HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

WHEN INVASIVE CARDIOLOGY METHODS ARE NOT APPLICABLE

Download full text PDF
Issue: 
3
Year: 
2017

Professor A. Vertkin, MD; G. Knorring, Candidate of Medical Sciences A.I. Evdokimov Moscow State Medical and Dental University

Invasive cardiology has a great opportunity to improve the quality of life and the prognosis of patients with ischaemic heart disease, but with all significance, revascularization procedures are limited in large group of patients. Optimal medical therapy becomes the only alternative option for this group of patients, and for patients who already survived invasive manipulation this procedure can lasting many years. The potassium channels activator Cordinik (nicorandil) has many statistically significant opportunities; the efficacy of this drug has been shown in patients with ischaemic heart disease.

Keywords: 
cardiology
revascularization
ischaemic heart disease
angina pectoris
nicorandil



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Barbarash L.S., Artamonova G.V., Murashkovskij A.L. i dr. Organizatsionnye podhody k okazaniju pomoschi patsientam s ostrym koronarnym sindromom // Doktor.Ru. – 2013; 6 (84): 24–8.
  2. Buza V.V., Karpov JuA. Chreskozhnye koronarnye vmeshatel'stva u bol'nyh stabil'noj IBS – 2012 // Rus. med. zhurn. Kardiologija. – 2012; 25: 1270–4.
  3. Boden W., O'Rourke R., Teo K. et al. Optimal medical therapy with or without PCI for stable coronary disease // N. Engl. J. Med. – 2007; 356: 1503–16.
  4. Dagenais G., Lu J., Faxon D. et al. Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease // Circulation. – 2011; 123: 1492–500.
  5. Nishigaki K., Yamazaki T., Kitabatake A. et al. Japanese Stable Angina Pectoris Study Investigators. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study // JACC Cardiovasc. Interv. – 2008; 1: 469–79.
  6. Murry C., Jenning R., Reimer K. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium // Circulation. – 1986; 74 (5): 1122–36.
  7. Kharbanda R. Cardiac conditioning: a review of evolving strategies to reduce ischemia-reperfusion injury // Heart. – 2010; 96: 1179–86.
  8. Jaffe M., Quinn N. Warm-up phenomenon in angina pectoris // Lancet. – 1980; 2: 934–6.
  9. Li J., Huang C., Jiang H. et al. Ischemic preconditioning detected by treadmill exercise tests in patients with stable angina // Angiology. – 2003; 54 (1): 45–50.
  10. Kay I., Kittelson J., Stewart R. Collateral recruitment and “warm-up” after first exercise in ischemic heart disease // Am. Heart J. – 2000; 140: 121–5.
  11. Aronov D.M., Lupanov V.P. Funktsional'nye proby v kardiologii / M.: Medpress-Inform, 2007; s. 212–3.
  12. Opie L. Preconditioning and metabolic antiishemic agents // Eur. Heart J. – 2003; 24: 1854–6.
  13. Petrischev N.N., Shljahto E.V., Tsyrlin V.A. i dr. Rol' svobodnyh radikalov kisloroda v mehanizmah lokal'nogo i distantnogo ishemicheskogo prekonditsionirovanija miokarda // Vestn. RAMN. – 2006; 8: 10–5.
  14. Hausenloy D., Ong S., Yellon D. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning // Basic Res. Cardiol. – 2009; 104 (2): 189–202.
  15. Bojtsov S.A. Patogenez hronicheskoj formy ishemicheskoj bolezni serdtsa. V kn.: Rukovodstvo po aterosklerozu i ishemicheskoj bolezni serdtsa. Pod red. E.I. Chazova i dr. / M.: Media Medika, 2007; s. 330–48.
  16. Kinoshita M., Sakai K. Pharmacology and Therapeutic Effects of Nicorandil // Cardiovasc. Drugs Ther. – 1990; 4: 1075–88.
  17. Meany T., Richardson P., Camm A. et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris // Am. J. Cardiol. – 1989; 63: 66–70.
  18. Airaksinen K., Huikuri H. Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty // J. Am. Coll. Cardiol. – 1997; 29 (5): 1035.
  19. Sakamoto T., Kaikita K., Miyamoto S. et al. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease // Circ. J. – 2004; 68: 232–56.
  20. Izumiya Y., Kojima S., Araki S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. – 2011; 214 (2): 415–21.
  21. Markham A., Plosker G., Goa K. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardio-protective effects // Drugs. – 2000; 60: 955–74.
  22. Sekiya M., Sato M., Funada J. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. – 2005; 46 (1): 63–7.
  23. Kasama S., Toyama T., Sumino H. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction // J. Nucl. Med. – 2007; 48 (10): 1676–82.
  24. Kasama S., Toyama T., Hatori T. et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy // Am. Heart J. – 2005; 150 (3): 477.e1–477.e8.
  25. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial // Lancet. – 2002; 359: 1269–75.
  26. VNOK. Ratsional'naja farmakoterapija bol'nyh SSZ. Rossijskie rekomendatsii // Kardiovask. terapija i profilaktika. – 2009; 8 (6, Pril. 4): 12.
  27. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease // Eur. Heart J. – 2013; 34: 2949–3003.
  28. Rezvanova Ju.A., Adamchik A.S. Otsenka antiishemicheskoj i kardioprotektivnoj effektivnosti nikorandila u patsientov so stabil'noj stenokardiej // Kardiologija. – 2015; 8 (55): 21–5.
  29. Bulahova E.Ju. i dr. Klinicheskie preimuschestva terapii nikorandilom v sravnenii s izosorbid-5-mononitratom u bol'nyh IBS // Serdtse. – 2013; 12 (2): 83–7.
  30. Rjabihin E.A., Mozhejko M.E., Krasil'nikova Ju.A. i dr. Dopolnitel'nye vozmozhnosti v lechenii ishemicheskoj bolezni serdtsa, oslozhnennoj hronicheskoj serdechnoj nedostatochnost'ju s nizkoj fraktsiej vybrosa levogo zheludochka // Serdechnaja nedostatochnost'. – 2016; 17 (1): 3–9.
  31. Sakata Ja. i dr. Snizhenie smertnosti u bol'nyh posle ostrogo infarkta miokarda, svjazannoe s peroral'noj terapiej nikorandilom pri vypiske iz statsionara // Ros. kardiol. zhurn. – 2012; 5 (97): 90–7.
  32. Hausenloy D., Yellon D. Preconditioning and postconditioning: united at reperfusion // Pharmacol. Ther. – 2007; 116 (2): 173–91.
  33. Granfeld A., Lefer D., Vinten-Johansen J. Protective ischemia in patients: preconditioning and postconditioning // Cadiovasc. Res. – 2009; 83 (2): 234–46.
  34. Van Vunren D., Lochner A. Ischemic preconditioning: from bench to bedside // Cardiovasc. J. Afr. – 2008; 19 (6): 311–20.
  35. Natsional'nye klinicheskie rekomendatsii «Ostryj infarkt miokarda s pod'emom segmenta ST elektrokardiogrammy: reabilitatsija i vtorichnaja profilaktika» // Kardiosomatika. – 2014; 5 (Pril. 1).
  36. Martsevich S.Ju., Kutishenko N.P., Deev A.D. i dr. Izuchenie vlijanija nikorandila na kachestvo zhizni patsientov so stabil'noj stenokardiej v ramkah issledovanija KVAZAR // Ratsional'naja farmakoterapija v kardiologii. – 2016; 12 (6): 654–60.
  37. Martsevich S.Ju., Kutishenko N.P., Deev A.D. i dr. Sravnitel'naja otsenka antianginal'noj effektivnosti i bezopasnosti preparata nikorandil na fone bazisnoj terapii β-adrenoblokatorami u bol'nyh ishemicheskoj bolezn'ju serdtsa so stabil'noj stenokardiej // Kardiologija. – 2016; 56 (10): 30–4.
  38. Voronina V.P., Martsevich S.Ju., Kutishenko N.P. Otsenka antiishemicheskogo i antianginal'nogo effektov nikorandila s pomosch'ju nagruzochnyh testov na tredmile v ramkah issledovanija KVAZAR // Ros. kardiol. zhurn. – 2017; 3 (143).